News & Presentations
Previous Article   |   Next Article
Regulatory Notice, RNS Announcements | 31 Mar 2016

Total Voting Rights

London: Thursday, March 31, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2016, the issued share capital of Chi-Med consisted of 60,283,118 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 60,283,118 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority’s Disclosure Rules and Transparency Rules.

 

Ends

 

Contact

Chi-Med

Christian Hogg, CEO

+852 2121 8200

International Media Enquiries

Anthony Carlisle, Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)

U.S. Based Media Enquiries

Brad Miles, BMC Communications

+1 (917) 570 7340

Susan Duffy, BMC Communications

+1 (917) 499 8887

Investor Relations

Jillian Connell, The Trout Group

+1 (646) 378 2956

David Dible, Citigate Dewe Rogerson

+44 20 7638 9571
+44 7967 566 919 (Mobile)

Panmure Gordon (UK) Limited

Richard Gray / Andrew Potts

+44 20 7886 2500

 

Notes to Editors

About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.